ZS Pharma announces positive top-line results from HARMONIZE (ZS004) phase 3 trial
ZS Pharma announced positive top-line results from HARMONIZE (ZS004), its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia. Preliminary analyses showed that all three doses of once daily ZS-9 met the primary endpoint. September 23, 2014